Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Kudchadkar · SciRah

Researcher profile · Semantic Scholar

R. Kudchadkar

Share profile

R. Kudchadkar — researcher profile on SciRah

h-index: 54
Works: 196
Citations: 16K

Most-cited papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber, M. Mandalà, M. Del Vecchio, H. Gogas +30 more
2017New England Journal of Medicine1,978 citations Open access
Semantic Scholar
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
H. Tawbi, P. Forsyth, A. Algazi, O. Hamid +18 more
2018New England Journal of Medicine1,129 citations Open access
Semantic Scholar
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
P. Nghiem, S. Bhatia, E. Lipson, R. Kudchadkar +27 more
2016New England Journal of Medicine1,129 citations Open access
Semantic Scholar
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
P. Nghiem, S. Bhatia, E. Lipson, W. Sharfman +27 more
2018Journal of Clinical Oncology336 citations Open access
Semantic Scholar
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
G. Long, J. Weber, J. Infante, Kevin B. Kim +22 more
2016Journal of Clinical Oncology290 citations
Semantic Scholar
Metastatic melanoma
R. Kudchadkar, M. Lowe, Mohammad K. Khan, Stephanie M. McBrien
2019Ca244 citations Open access
Semantic Scholar
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
H. Tawbi, P. Forsyth, F. Hodi, A. Algazi +21 more
2021The Lancet Oncology242 citations Open access
Semantic Scholar
Systemic Therapy for Melanoma: ASCO Guideline.
R. Seth, H. Messersmith, V. Kaur, J. Kirkwood +25 more
2020Journal of Clinical Oncology237 citations
Semantic Scholar
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
S. Topalian, S. Bhatia, A. Amin, R. Kudchadkar +20 more
2020Journal of Clinical Oncology218 citations Open access
Semantic Scholar
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L. Barber, Shunsuke Sakai, R. Kudchadkar, S. Fling +11 more
2019Science Translational Medicine187 citations Open access
Semantic Scholar
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
R. Dummer, A. Guminksi, R. Gutzmer, J. Lear +13 more
2019British Journal of Dermatology185 citations Open access
Semantic Scholar
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
J. Lear, M. Migden, K. Lewis, A. Chang +16 more
2017Journal of the European Academy of Dermatology and Venereology182 citations Open access
Semantic Scholar
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
D. Qian, T. Kleber, B. Brammer, Karen M. Xu +10 more
2021The Lancet Oncology177 citations
Semantic Scholar
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
R. Dummer, A. Guminski, R. Gutzmer, L. Dirix +19 more
2016Journal of American Academy of Dermatology167 citations Open access
Semantic Scholar
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy
M. A. Bilen, D. Martini, Yuan Liu, C. Lewis +17 more
2018Cancer162 citations Open access
Semantic Scholar
Prevention of dietary fat-fueled ketogenesis attenuates BRAF V600E tumor growth
Siyuan Xia, Rui-Ting Lin, Ling-Tao Jin, Liang Zhao +24 more
2017Cell Metabolism157 citations Open access
Semantic Scholar
Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)
S. Topalian, S. Bhatia, A. Hollebecque, A. Awada +15 more
2017Clinical Trials129 citations
Semantic Scholar
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
M. A. Bilen, J. Shabto, D. Martini, Yuan Liu +16 more
2019BMC Cancer125 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
H. Tawbi, Peter A. Forsyth, A. Algazi, O. Hamid +16 more
2017119 citations
Semantic Scholar
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
P. Nghiem, S. Bhatia, E. Lipson, W. Sharfman +25 more
2021Journal for ImmunoTherapy of Cancer118 citations Open access
Semantic Scholar
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
H. Tawbi, P. Forsyth, F. Hodi, C. Lao +19 more
2021Neuro-Oncology95 citations Open access
Semantic Scholar
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.
A. Tarhini, R. Kudchadkar
2018Cancer Treatment Reviews73 citations Open access
Semantic Scholar
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma
J. Bendell, V. André, A. Ho, R. Kudchadkar +7 more
2018Clinical Cancer Research64 citations Open access
Semantic Scholar
Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma
Z. Eroglu, Y. Chen, G. Gibney, J. Weber +17 more
2018Clinical Cancer Research63 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma
K. Grossmann, M. Othus, S. Patel, A. Tarhini +27 more
2021Cancer Discovery61 citations Open access
Semantic Scholar
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Kevin E. Fisher, Lin-Sheng Zhang, Jason Wang, G. Smith +21 more
2016Journal of Molecular Diagnostics59 citations Open access
Semantic Scholar
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials
D. Martini, Meredith R. Kline, Yuan Liu, J. Shabto +20 more
2020Cancer58 citations Open access
Semantic Scholar
A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.
A. Shoushtari, R. Kudchadkar, K. Panageas, R. Murthy +12 more
201654 citations
Semantic Scholar
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.
S. Topalian, S. Bhatia, R. Kudchadkar, A. Amin +15 more
201836 citations
Semantic Scholar
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization
Alexa O. Levey, M. Elsayed, D. Lawson, R. Ermentrout +5 more
2020Cardiovascular and Interventional Radiology35 citations
Semantic Scholar
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers
Liang Zhao, Jun Fan, Siyuan Xia, Yaozhu Pan +18 more
2017Journal of Biological Chemistry35 citations Open access
Semantic Scholar
A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors
C. Yam, Xiao-Wei Xu, M. Davies, P. Gimotty +17 more
2017Clinical Cancer Research35 citations Open access
Semantic Scholar
The evolving landscape of immunotherapy in solid tumors
J. Keilson, H. Knochelmann, C. Paulos, R. Kudchadkar +1 more
2021Journal of Surgical Oncology31 citations Open access
Semantic Scholar
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
A. Eggermont, A. Meshcheryakov, V. Atkinson, C. Blank +30 more
2021European Journal of Cancer27 citations Open access
Semantic Scholar
FcγRIIB is a T cell checkpoint in antitumor immunity
C. Farley, A. Morris, Marvi Tariq, K. Bennion +4 more
2021JCI Insight27 citations Open access
Semantic Scholar
Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma
D. Oliver, K. Patel, J. Switchenko, Douglas C. Parker +4 more
2016Melanoma research25 citations Open access
Semantic Scholar
FcγRIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer
K. Bennion, Marvi Tariq, Megan M. Wyatt, Charlotte Duneton +5 more
2023Science Translational Medicine21 citations Open access
Semantic Scholar
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F. Hodi, P. Chapman, M. Sznol, C. Lao +16 more
2020Melanoma research19 citations Open access
Semantic Scholar
Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy
Tyler J. Beardslee, A. Draper, R. Kudchadkar
2018Journal of Oncology Pharmacy Practice19 citations
Semantic Scholar
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
Chase W. Kwon, Rajini K. Murthy, R. Kudchadkar, B. Stoff
2020JAAD Case Reports18 citations Open access
Semantic Scholar
Dietary supplement chondroitin-4-sulfate exhibits oncogene-specific pro-tumor effects on BRAF V600E melanoma cells
Rui-Ting Lin, Siyuan Xia, Changliang Shan, Dong Chen +15 more
2018Molecules and Cells17 citations Open access
Semantic Scholar
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry
A. Sekulic, S. Yoo, R. Kudchadkar, J. Guillen +9 more
2022PLoS ONE16 citations Open access
Semantic Scholar
Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).
R. Kudchadkar, M. Yushak, D. Lawson, K. Delman +8 more
201816 citations
Semantic Scholar
Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
R. Kudchadkar, O. Michielin, A. V. van Akkooi
2018American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting15 citations Open access
Semantic Scholar
Relationship between Physician-Adjudicated Adverse Events and Patient-Reported Health-Related Quality of Life in a Phase II Clinical Trial (NCT01143402) of Patients with Metastatic Uveal Melanoma
T. Atkinson, J. Hay, A. Shoushtari, Yue-Lin Li +22 more
2016Journal of Cancer Research and Clinical Oncology12 citations Open access
Semantic Scholar
Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx.
Marcus A. Carden, M. Gaddh, A. Hoskote, Michael Brown +8 more
2020Blood Advances11 citations Open access
Semantic Scholar
The Impact of Obesity on Surgically Treated Locoregional Melanoma
Constance S. Harrell Shreckengost, Marvi Tariq, C. Farley, Chao Zhang +3 more
2021Annals of Surgical Oncology10 citations
Semantic Scholar
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
D. Martini, Yuan Liu, J. Shabto, C. Lewis +18 more
2019Investigational new drugs10 citations Open access
Semantic Scholar
Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
D. Hogg, P. Chapman, M. Sznol, C. Lao +12 more
20178 citations
Semantic Scholar
A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.
A. Dowlati, H. Rugo, R. Harvey, R. Kudchadkar +10 more
20178 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Lawson×10
Invite
D. Lawson — researcher profile on SciRah
N. Khushalani×8
Invite
N. Khushalani — researcher profile on SciRah
K. Lewis×8
Invite
K. Lewis — researcher profile on SciRah
C. Lao×8
Invite
C. Lao — researcher profile on SciRah

×8

Invite

W. Sharfman — researcher profile on SciRah

Invite

M. Atkins — researcher profile on SciRah

Invite

S. Bhatia — researcher profile on SciRah

Invite

P. Nghiem — researcher profile on SciRah

Invite

O. Hamid — researcher profile on SciRah

Invite

A. Tarhini — researcher profile on SciRah

Invite

A. Pavlick — researcher profile on SciRah

Invite

S. Topalian — researcher profile on SciRah